Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -39.76% is 21% above its 5-year average of -50.25%, near the high end of its 5-year range (-153.72%–-28.83%).
As of the fiscal period ended Tuesday, June 30, 2026. 47.81% above its 12-month average of -76.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -39.76%.
RETURN ON EQUITY (ROE)
-39.76%
RETURN ON EQUITY (ROE) AVG TTM
-76.18%
RETURN ON EQUITY (ROE) AVG 3Y
-53.88%
RETURN ON EQUITY (ROE) AVG 5Y
-50.25%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+47.81%
CURRENT VS 3Y AVG
+26.21%
CURRENT VS 5Y AVG
+20.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
+3.50%
vs the sector median at left
Optimi Health Corp.
Market Cap
$13.51M
Return on Equity (ROE)
-39.76%
TTM Avg
-76.18%
3Y Avg
-53.88%
5Y Avg
-50.25%
Market Cap
$13.60M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
Market Cap
$13.14M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
Market Cap
$13.92M
Return on Equity (ROE)
-372.67%
TTM Avg
-433.17%
3Y Avg
-292.89%
5Y Avg
-208.82%
Market Cap
$13.93M
Return on Equity (ROE)
-186.95%
TTM Avg
1198.98%
3Y Avg
241.18%
5Y Avg
112.17%
Market Cap
$12.95M
Return on Equity (ROE)
-810.41%
TTM Avg
-174.22%
3Y Avg
-126.94%
5Y Avg
-100.46%
Market Cap
$12.94M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.78%
3Y Avg
-138.63%
5Y Avg
-109.18%
Market Cap
$14.11M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.14M
Return on Equity (ROE)
-19.08%
TTM Avg
-28.50%
3Y Avg
-28.27%
5Y Avg
-100.79%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Optimi Health Corp. (OPTH) | $13.51M | -39.76% | -76.18% | -53.88% | -50.25% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.60M | -69.47% | -55.64% | -44.95% | -41.56% |
| IN8bio, Inc. (INAB)vs › | $13.14M | -101.66% | -140.38% | -131.64% | -101.94% |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | -372.67% | -433.17% | -292.89% | -208.82% |
| Vyome Holdings, Inc. (HIND)vs › | $13.93M | -186.95% | 1198.98% | 241.18% | 112.17% |
| Passage Bio, Inc. (PASG)vs › | $12.95M | -810.41% | -174.22% | -126.94% | -100.46% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.94M | -74.73% | -265.78% | -138.63% | -109.18% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.11M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.14M | -19.08% | -28.50% | -28.27% | -100.79% |
| Cytosorbents Corporation (CTSO)vs › | $12.73M | N/A | -162.71% | -135.96% | -98.83% |
ROE
-39.8%
ROA
-27.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -39.76% |
| 2026-03-31 | -153.72% |
| 2025-12-31 | -79.51% |
| 2025-09-30 | -56.10% |
| 2025-06-30 | -51.83% |
| 2025-03-31 | -57.85% |
| 2024-12-31 | -73.38% |
| 2024-09-30 | -63.14% |
| 2024-06-30 | -53.45% |
| 2024-03-31 | -49.55% |
| 2023-12-31 | -43.26% |
| 2023-09-30 | -40.01% |
| 2023-06-30 | -38.67% |
| 2023-03-31 | -34.88% |
| 2022-12-31 | -36.65% |
| 2022-09-30 | -51.59% |
| 2022-06-30 | -52.97% |
| 2022-03-31 | -56.24% |
| 2021-12-31 | -47.03% |
| 2021-09-30 | -28.83% |
